APA (7th ed.) Citation

Falavigna, M., Deyneli, O., Seyam, A., Mustafa, N., Giorgi, M., Gabriel, Z., . . . Mihajlović, J. (2022). EE53 The Net Monetary Benefit of Introducing Sodium-Glucose Cotransporter-2 Inhibitors in Middle-Income Countries. Value in Health, 25(12), S63. https://doi.org/10.1016/j.jval.2022.09.306

Chicago Style (17th ed.) Citation

Falavigna, M., et al. "EE53 The Net Monetary Benefit of Introducing Sodium-Glucose Cotransporter-2 Inhibitors in Middle-Income Countries." Value in Health 25, no. 12 (2022): S63. https://doi.org/10.1016/j.jval.2022.09.306.

MLA (9th ed.) Citation

Falavigna, M., et al. "EE53 The Net Monetary Benefit of Introducing Sodium-Glucose Cotransporter-2 Inhibitors in Middle-Income Countries." Value in Health, vol. 25, no. 12, 2022, p. S63, https://doi.org/10.1016/j.jval.2022.09.306.